Does the media refer more to UTHR or REGN?

In the previous week, Regeneron Pharmaceuticals had 19 more articles in the media than United Therapeutics. MarketBeat recorded 43 mentions for Regeneron Pharmaceuticals and 24 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.92 beat Regeneron Pharmaceuticals' score of 0.52 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 12 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 15 Very Positive mention(s) 4 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media favor ARGX or UTHR?

In the previous week, United Therapeutics had 11 more articles in the media than argenex. MarketBeat recorded 24 mentions for United Therapeutics and 13 mentions for argenex. United Therapeutics' average media sentiment score of 0.92 beat argenex's score of 0.59 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 2 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 12 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer UTHR or MRNA?

In the previous week, Moderna had 40 more articles in the media than United Therapeutics. MarketBeat recorded 64 mentions for Moderna and 24 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.92 beat Moderna's score of 0.58 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 12 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 21 Very Positive mention(s) 13 Positive mention(s) 11 Neutral mention(s) 5 Negative mention(s) 4 Very Negative mention(s) Positive

Does the media refer more to UTHR or NTRA?

In the previous week, United Therapeutics had 5 more articles in the media than Natera. MarketBeat recorded 24 mentions for United Therapeutics and 19 mentions for Natera. Natera's average media sentiment score of 1.07 beat United Therapeutics' score of 0.92 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 12 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Natera 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RVMD or UTHR?

In the previous week, United Therapeutics had 7 more articles in the media than Revolution Medicines. MarketBeat recorded 24 mentions for United Therapeutics and 17 mentions for Revolution Medicines. United Therapeutics' average media sentiment score of 0.92 beat Revolution Medicines' score of 0.78 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 7 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive United Therapeutics 12 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

United Therapeutics (UTHR) Competitors

$487.61 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

UTHR vs. REGN, ARGX, MRNA, NTRA, and RVMD

Should you buy United Therapeutics stock or one of its competitors? United Therapeutics's main competitors and comparable companies include Regeneron Pharmaceuticals (REGN), argenex (ARGX), Moderna (MRNA), Natera (NTRA), and Revolution Medicines (RVMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does United Therapeutics compare to Regeneron Pharmaceuticals?

United Therapeutics (NASDAQ:UTHR) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

United Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

United Therapeutics has a net margin of 41.56% compared to Regeneron Pharmaceuticals' net margin of 27.86%. United Therapeutics' return on equity of 20.18% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

In the previous week, Regeneron Pharmaceuticals had 19 more articles in the media than United Therapeutics. MarketBeat recorded 43 mentions for Regeneron Pharmaceuticals and 24 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.92 beat Regeneron Pharmaceuticals' score of 0.52 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	12 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	15 Very Positive mention(s)	4 Positive mention(s)	19 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Regeneron Pharmaceuticals has higher revenue and earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.57	$1.33B	$27.95	17.45
Regeneron Pharmaceuticals	$14.34B	5.94	$4.50B	$40.46	20.46

United Therapeutics presently has a consensus target price of $646.00, suggesting a potential upside of 32.48%. Regeneron Pharmaceuticals has a consensus target price of $800.36, suggesting a potential downside of 3.31%. Given United Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe United Therapeutics is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

United Therapeutics beats Regeneron Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does United Therapeutics compare to argenex?

argenex (NASDAQ:ARGX) and United Therapeutics (NASDAQ:UTHR) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

60.3% of argenex shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 2.4% of argenex shares are owned by company insiders. Comparatively, 8.6% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

argenex presently has a consensus target price of $1,158.61, indicating a potential upside of 12.14%. United Therapeutics has a consensus target price of $646.00, indicating a potential upside of 32.48%. Given United Therapeutics' higher possible upside, analysts clearly believe United Therapeutics is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has a net margin of 41.56% compared to argenex's net margin of 32.19%. argenex's return on equity of 43.59% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
United Therapeutics	41.56%	20.18%	17.98%

In the previous week, United Therapeutics had 11 more articles in the media than argenex. MarketBeat recorded 24 mentions for United Therapeutics and 13 mentions for argenex. United Therapeutics' average media sentiment score of 0.92 beat argenex's score of 0.59 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	2 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	12 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has lower revenue, but higher earnings than argenex. United Therapeutics is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	15.21	$1.29B	$26.04	39.68
United Therapeutics	$3.18B	6.57	$1.33B	$27.95	17.45

argenex has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

Summary

United Therapeutics beats argenex on 9 of the 17 factors compared between the two stocks.

How does United Therapeutics compare to Moderna?

United Therapeutics (NASDAQ:UTHR) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

United Therapeutics currently has a consensus target price of $646.00, indicating a potential upside of 32.48%. Moderna has a consensus target price of $76.72, indicating a potential downside of 47.29%. Given United Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe United Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

United Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Moderna has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

United Therapeutics has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.57	$1.33B	$27.95	17.45
Moderna	$1.94B	29.89	-$2.82B	-$7.99	N/A

In the previous week, Moderna had 40 more articles in the media than United Therapeutics. MarketBeat recorded 64 mentions for Moderna and 24 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.92 beat Moderna's score of 0.58 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	12 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	21 Very Positive mention(s)	13 Positive mention(s)	11 Neutral mention(s)	5 Negative mention(s)	4 Very Negative mention(s)	Positive

United Therapeutics has a net margin of 41.56% compared to Moderna's net margin of -141.43%. United Therapeutics' return on equity of 20.18% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Moderna	-141.43%	-28.30%	-19.39%

Summary

United Therapeutics beats Moderna on 12 of the 16 factors compared between the two stocks.

How does United Therapeutics compare to Natera?

United Therapeutics (NASDAQ:UTHR) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

United Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Natera has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

In the previous week, United Therapeutics had 5 more articles in the media than Natera. MarketBeat recorded 24 mentions for United Therapeutics and 19 mentions for Natera. Natera's average media sentiment score of 1.07 beat United Therapeutics' score of 0.92 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	12 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	14 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a net margin of 41.56% compared to Natera's net margin of -7.11%. United Therapeutics' return on equity of 20.18% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Natera	-7.11%	-11.38%	-7.87%

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 8.6% of United Therapeutics shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

United Therapeutics currently has a consensus target price of $646.00, indicating a potential upside of 32.48%. Natera has a consensus target price of $319.38, indicating a potential downside of 2.68%. Given United Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe United Therapeutics is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

United Therapeutics has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.57	$1.33B	$27.95	17.45
Natera	$2.31B	20.51	-$208.16M	-$1.36	N/A

Summary

United Therapeutics beats Natera on 11 of the 17 factors compared between the two stocks.

How does United Therapeutics compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and United Therapeutics (NASDAQ:UTHR) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

United Therapeutics has a net margin of 41.56% compared to Revolution Medicines' net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
United Therapeutics	41.56%	20.18%	17.98%

Revolution Medicines presently has a consensus price target of $200.74, indicating a potential downside of 4.42%. United Therapeutics has a consensus price target of $646.00, indicating a potential upside of 32.48%. Given United Therapeutics' higher possible upside, analysts clearly believe United Therapeutics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

United Therapeutics has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,887.37	-$1.13B	-$8.82	N/A
United Therapeutics	$3.18B	6.57	$1.33B	$27.95	17.45

In the previous week, United Therapeutics had 7 more articles in the media than Revolution Medicines. MarketBeat recorded 24 mentions for United Therapeutics and 17 mentions for Revolution Medicines. United Therapeutics' average media sentiment score of 0.92 beat Revolution Medicines' score of 0.78 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	7 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
United Therapeutics	12 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Summary

United Therapeutics beats Revolution Medicines on 11 of the 17 factors compared between the two stocks.

Get United Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UTHR vs. The Competition

Export

Metric	United Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$20.91B	$3.99B	$7.21B	$12.89B
Dividend Yield	N/A	3.60%	2.54%	9.13%
P/E Ratio	17.45	12.71	273.84	25.45
Price / Sales	6.57	1,344.29	625.56	100.83
Price / Cash	14.78	45.00	28.92	35.62
Price / Book	2.96	16.40	11.01	6.39
Net Income	$1.33B	-$22.85M	$3.49B	$358.69M
7 Day Performance	-4.46%	1.43%	1.63%	0.22%
1 Month Performance	-9.51%	6.00%	4.42%	-0.10%
1 Year Performance	21.74%	49.38%	24.21%	14.04%

United Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UTHR United Therapeutics	4.67 of 5 stars	$487.61 flat	$646.00 +32.5%	+21.7%	$20.91B	$3.18B	17.45	1,400
REGN Regeneron Pharmaceuticals	4.0767 of 5 stars	$799.08 +0.6%	$800.36 +0.2%	+44.4%	$81.77B	$14.34B	19.75	15,410	Positive News
ARGX argenex	4.0414 of 5 stars	$1,031.66 +0.8%	$1,158.61 +12.3%	+37.6%	$64.01B	$4.25B	39.62	1,863	Analyst Upgrade
MRNA Moderna	1.469 of 5 stars	$140.34 +1.7%	$80.53 -42.6%	+479.0%	$55.09B	$1.94B	N/A	4,700	Gap Down
NTRA Natera	2.4691 of 5 stars	$321.96 -1.3%	$319.38 -0.8%	+95.3%	$47.03B	$2.31B	N/A	6,140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UTHR) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

United Therapeutics (UTHR) Competitors

UTHR vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does United Therapeutics compare to Regeneron Pharmaceuticals?

Summary

How does United Therapeutics compare to argenex?

Summary

How does United Therapeutics compare to Moderna?

Summary

How does United Therapeutics compare to Natera?

Summary

How does United Therapeutics compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR vs. The Competition

United Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

United Therapeutics (UTHR) Competitors

UTHR vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does United Therapeutics compare to Regeneron Pharmaceuticals?

Which has more risk and volatility, UTHR or REGN?

Is UTHR or REGN more profitable?

Does the media refer more to UTHR or REGN?

Do insiders & institutionals hold more shares of UTHR or REGN?

Which has preferable valuation & earnings, UTHR or REGN?

Do analysts rate UTHR or REGN?

Summary

How does United Therapeutics compare to argenex?

Do institutionals and insiders have more ownership in ARGX or UTHR?

Do analysts prefer ARGX or UTHR?

Is ARGX or UTHR more profitable?

Does the media favor ARGX or UTHR?

Which has stronger valuation & earnings, ARGX or UTHR?

Which has more volatility & risk, ARGX or UTHR?

Summary

How does United Therapeutics compare to Moderna?

Do insiders & institutionals believe in UTHR or MRNA?

Do analysts rate UTHR or MRNA?

Which has more risk & volatility, UTHR or MRNA?

Which has stronger valuation and earnings, UTHR or MRNA?

Does the media prefer UTHR or MRNA?

Is UTHR or MRNA more profitable?

Summary

How does United Therapeutics compare to Natera?

Which has more risk & volatility, UTHR or NTRA?

Does the media refer more to UTHR or NTRA?

Is UTHR or NTRA more profitable?

Do insiders and institutionals believe in UTHR or NTRA?

Do analysts rate UTHR or NTRA?

Which has higher valuation & earnings, UTHR or NTRA?

Summary

How does United Therapeutics compare to Revolution Medicines?

Is RVMD or UTHR more profitable?

Do analysts recommend RVMD or UTHR?

Do insiders and institutionals believe in RVMD or UTHR?

Which has better valuation & earnings, RVMD or UTHR?

Does the media prefer RVMD or UTHR?

Which has more volatility & risk, RVMD or UTHR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR vs. The Competition

United Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools